MARKET

NXTC

NXTC

NextCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.38
+0.17
+1.67%
After Hours: 10.38 0 0.00% 13:56 11/27 EST
OPEN
10.23
PREV CLOSE
10.21
HIGH
10.70
LOW
10.13
VOLUME
132.89K
TURNOVER
--
52 WEEK HIGH
70.98
52 WEEK LOW
7.91
MARKET CAP
286.00M
P/E (TTM)
-6.9857
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st. An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company’s website at www.nextcure.com and archived on the website for 30 days.About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.comCautionary Statement Regarding Forward-Looking Statements Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change. CONTACT: Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com
GlobeNewswire · 5d ago
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 09/25 11:37
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston
GlobeNewswire · 09/14 21:05
NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference
BELTSVILLE, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Morgan
GlobeNewswire · 09/08 13:05
What's Next For NextCure
Today, we look at a small biotech concern that has entered 'Busted IPO' territory after a recent trial setback.
Seeking Alpha - Article · 08/24 18:03
NextCure EPS misses by $0.03
NextCure (NASDAQ:NXTC): Q2 GAAP EPS of -$0.53 misses by $0.03. Cash, cash equivalents and marketable securities of $309.3M. Press release
seekingalpha · 08/07 01:50
NextCure Reports Second Quarter 2020 Financial Results
BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
GlobeNewswire · 08/06 20:03
NextCure to Present at BTIG Virtual Biotechnology Conference
BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
GlobeNewswire · 08/05 12:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NXTC. Analyze the recent business situations of NextCure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NXTC stock price target is 23.67 with a high estimate of 55.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 19.40M
% Owned: 70.41%
Shares Outstanding: 27.55M
TypeInstitutionsShares
Increased
23
3.94M
New
39
-3.86M
Decreased
24
2.06M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.12%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
David Kabakoff
President/Chief Executive Officer/Director
Michael Richman
Chief Financial Officer
Steven Cobourn
Chief Operating Officer
Timothy Mayer
Senior Vice President
Linda Liu
Chief Scientific Officer
Sol Langermann
Other
James Bingham
Director
John Houston
Independent Director
Elaine Jones
Independent Director
Chau Khuong
Independent Director
Briggs Morrison
Independent Director
Garry Nicholson
Independent Director
Stephen Webster
Independent Director
Stella Xu
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NXTC
Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of NextCure Inc stock information, including NASDAQ:NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.